tiprankstipranks
I-Mab Showcases Promising Gastric Cancer Drug Results
Company Announcements

I-Mab Showcases Promising Gastric Cancer Drug Results

I-MAB (IMAB) has released an update.

Don't Miss our Black Friday Offers:

I-Mab, a global biotech company, has reported promising results for their innovative cancer drug givastomig at the ESMO 2024 Congress. The drug, intended for advanced gastric cancer treatment, demonstrated efficacy and safety in Phase 1 trials, with positive responses even in heavily pre-treated patients. A Phase 1b study is also in progress to examine givastomig’s potential as a front-line therapy in combination with standard-of-care treatments.

For further insights into IMAB stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskI-Mab’s Third Quarter Results: Progress in Cancer Immunotherapies
TipRanks Auto-Generated NewsdeskI-Mab’s Promising Q3 Results and Strategic Moves
TheFlyI-Mab reports Q3 EPS (25c) vs. (39c) last year
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App